Showing 2051-2060 of 2652 results for "".
- Aldeyra Therapeutics Announces Planned Pivotal Clinical Trial for RP Drug Candidatehttps://modernod.com/news/aldeyra-therapeutics-announces-planned-pivotal-clinical-trial-for-retinitis-pigmentosa-drug-candidate/2482247/Aldeyra Therapeutics hosted the Aldeyra 2024 Research & Development Day with investors and financial analysts in New York City on April 25 where it presented recent pipeline developments relating to the RASP modulation platform and ADX-2191 for the treatment of retinitis pigmentosa.
- Pantheon Vision Secures a Second Tranche of Funding to Advance Bioengineered Corneal Implantshttps://modernod.com/news/pantheon-vision-secures-a-second-tranche-of-funding-to-advance-bioengineered-corneal-implants/2482197/Pantheon Vision, a pre-clinical stage medical device company developing bioengineered corneal implants, announced the closing of $1.8 million in a second tranche from KeraLink International (KLI). This comes following a previous $2.5 million investment from KLI last year, bringing the total
- Nanoscope Announces Topline Results from Phase 2b Trial of MCO-010 for Retinitis Pigmentosahttps://modernod.com/news/nanoscope-announces-topline-results-from-randomized-phase-2b-trial-of-mco-010-for-retinitis-pigmentosa/2482183/Nanoscope Therapeutics announced positive topline results after the completion of the 2-year phase 2b RESTORE randomized, controlled clinical trial of its lead program, MCO-010, a mutation-agnostic gene therapy for patients with permanent and severe vision loss from advanced retini
- Staar Surgical Celebrates Three Million Implantable Collamer Lenseshttps://modernod.com/news/staar-surgical-celebrates-three-million-implantable-collamer-lenses/2482170/Staar Surgical announced that more than 3 million Implantable Collamer Lens (ICLs) have been sold globally.[1] “We extend our sincere gratitude to the surgeons and clinicians with whom we partner and to their patients who have chosen our ICLs for their vision correction
- New Study Shows Eylea HD with Extended 12- or 16-Week Dosing Demonstrated Noninferior Vision Gains to Standard of Care Eyleahttps://modernod.com/news/lancet-study-eylea-hd-with-extended-12-or-16-week-dosing-demonstrated-noninferior-vision-gains-to-standard-of-care-eylea/2482151/Regeneron announced The Lancet published 1-year results from the pivotal PULSAR and
- SDC Transitions its Ophthalmic Biometric Division to Ora Inc.https://modernod.com/news/sdc-transitions-its-ophthalmic-biometric-division-to-ora-inc/2482149/Statistics & Data Corporation (SDC) has decided to transition its ophthalmic biometric division to its partner Ora Inc. Since 2005, SDC’s partnership and common ownership with Ora has provided clinical trial services in ophthalmology, while allowing S
- Oculis Provides Updates on Late-Stage Clinical Trials; Announces Leadership Appointmentshttps://modernod.com/news/oculis-provides-updates-on-late-stage-clinical-trials-announces-leadership-appointments/2482135/Oculis provided updates its late-stage clinical trials, and also announced senior appointments to its management and advisory teams. The announcements were made during it R&D Day on Wednesday, February 28. “2024 promises to be another exciting year for Ocu
- EuroEyes Group Wins SMILE Refractive Laser Eye Surgery Awardhttps://modernod.com/news/euroeyes-group-wins-smile-refractive-laser-eye-surgery-award/2482087/LEC London announced that its parent company EuroEyes Clinic Group, has won the SMILE Laser Operations Award for conducting the highest number of SMILE (Small Incision Lenticule Extraction) laser operations in Europe last year (2023). EuroEyes performed a total of 9,550 SMILE operations
- Sydnexis Appoints Erin Horn as Vice President, Head of Market Accesshttps://modernod.com/news/sydnexis-names-erin-horn-as-vice-president-head-of-market-access/2482071/Sydnexis has announced the appointment of Erin Horn as Vice President, Head of Market Access. Ms. Horn will lead Sydnexis’ market access, pricing, contracting, and go-to-market strategies. With 25 years of industry experience, Ms. Horn has a track record of commercial success
- Zenni Optical Announces 2023 Eye Care Access Scholarship Winnershttps://modernod.com/news/zenni-optical-announces-2023-eye-care-access-scholarship-winners/2482062/Zenni Optical has awarded five optometry students with its 2023 Eye Care Access Scholarship. Now in its second year, the Zenni Eye Care Access Scholarship recognizes incoming students who want to provide eye care to communities in need everywhere.